Dimensional Fund Advisors LP grew its position in PAREXEL International Corporation (NASDAQ:PRXL) by 1.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 827,320 shares of the medical research company’s stock after acquiring an additional 14,855 shares during the quarter. Dimensional Fund Advisors LP owned about 1.63% of PAREXEL International Corporation worth $71,903,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PRXL. First Trust Advisors LP boosted its holdings in shares of PAREXEL International Corporation by 216.7% in the first quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock valued at $1,864,000 after acquiring an additional 20,210 shares during the period. Karp Capital Management Corp acquired a new stake in shares of PAREXEL International Corporation in the first quarter valued at approximately $671,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of PAREXEL International Corporation by 54.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 4,826 shares of the medical research company’s stock valued at $305,000 after acquiring an additional 1,699 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of PAREXEL International Corporation by 80.6% in the first quarter. JPMorgan Chase & Co. now owns 88,635 shares of the medical research company’s stock valued at $5,594,000 after acquiring an additional 39,558 shares during the period. Finally, Prudential Financial Inc. boosted its holdings in shares of PAREXEL International Corporation by 15.1% in the first quarter. Prudential Financial Inc. now owns 42,349 shares of the medical research company’s stock valued at $2,672,000 after acquiring an additional 5,551 shares during the period. 87.45% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently weighed in on PRXL. Zacks Investment Research downgraded PAREXEL International Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. BidaskClub downgraded PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Jefferies Group LLC reissued a “hold” rating and issued a $88.10 price objective on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Finally, Barclays PLC downgraded PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price objective for the company. in a report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $75.92.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) opened at 88.08 on Wednesday. The firm has a market capitalization of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77. The company’s 50 day moving average price is $87.85 and its 200 day moving average price is $79.27. PAREXEL International Corporation has a one year low of $51.16 and a one year high of $88.10.

PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. The business had revenue of $557.20 million during the quarter, compared to analyst estimates of $537.59 million. During the same quarter in the previous year, the firm posted $0.94 EPS. On average, analysts expect that PAREXEL International Corporation will post $4.06 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “PAREXEL International Corporation (PRXL) Shares Bought by Dimensional Fund Advisors LP” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/11/parexel-international-corporation-prxl-shares-bought-by-dimensional-fund-advisors-lp.html.

PAREXEL International Corporation Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.